Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

Study of Tecovirimat for Human Mpox Virus

NCT05534984 ·Status: TERMINATED ·Phase: PHASE3

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

NCT04392739 ·Status: COMPLETED ·Phase: PHASE4

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

NCT05745987 ·Status: RECRUITING ·Phase: PHASE4

SIGA-246 to Treat Smallpox

NCT00303225 ·Status: WITHDRAWN ·Phase: PHASE1

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

NCT05762523 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

NCT06771479 ·Status: RECRUITING ·Phase: PHASE1

Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia

NCT06223919 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

NCT02977715 ·Status: COMPLETED ·Phase: PHASE3

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

NCT00914732 ·Status: COMPLETED ·Phase: PHASE2

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

NCT00879762 ·Status: COMPLETED ·Phase: PHASE2

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039 ·Status: COMPLETED ·Phase: PHASE4

Dryvax Dilution-Prev Vacc Adults

NCT00032708 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537 ·Status: COMPLETED ·Phase: PHASE2

Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years

NCT05846243 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults

NCT00026611 ·Status: COMPLETED ·Phase: PHASE2

Phase I Trial of Smallpox Vaccine

NCT00046397 ·Status: COMPLETED ·Phase: PHASE1

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

NCT04627675 ·Status: TERMINATED ·Phase: PHASE1

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

NCT06549530 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371 ·Status: COMPLETED ·Phase: PHASE2

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

NCT01913353 ·Status: COMPLETED ·Phase: PHASE3

Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk

NCT05879965 ·Status: RECRUITING

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

NCT00189956 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

NCT00189917 ·Status: COMPLETED ·Phase: PHASE1